Failure of Fondaparinux in Autoimmune Heparin-Induced ThrombocytopeniaFunding None.
Heparin-induced thrombocytopenia (HIT) is an immune adverse reaction to heparin that is associated with life-threatening thrombotic complications. More rarely, HIT may begin after stopping of heparin or after flushes of heparin (autoimmune HIT). Fondaparinux has been proposed as a candidate treatment for HIT, but there are few data on its use in autoimmune HIT. An 86-year-old man with a history of diabetes mellitus, arterial hypertension, and hypercholesterolemia was admitted to our hospital for carotid endarterectomy. During surgery, only one heparin dose of 5,000 U was used. Platelet count started to decrease on the 11th day after surgery. Since the patient was not receiving heparin treatment/prophylaxis, HIT was not suspected. On day 19, platelet count was 61 × 103/μL, and the patient was investigated for a diagnosis of HIT. Immunoglobulin (Ig)-G-specific enzyme-linked immunosorbent assay (ELISA) was positive and HIT was confirmed by a platelet aggregation test; fondaparinux 5 mg once a day was started. During fondaparinux treatment, platelet count did not increase and a lower leg deep vein thrombosis occurred. Fondaparinux was stopped and rivaroxaban 15 mg twice a day was started. Platelet count returned to base line after 10 days from fondaparinux withdrawal. There was no thrombotic event or bleeding complication during rivaroxaban treatment. Anecdotal evidence suggests risk of failure of fondaparinux treatment for autoimmune HIT and supports the use of rivaroxaban for treatment of HIT, justifying larger studies.
Informed consent was obtained from the patient for the purpose of publication.
Received: 19 March 2020
Accepted: 11 May 2020
20 October 2020 (online)
© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).
Georg Thieme Verlag KG
Stuttgart · New York
- 1 Cosmi B. Current management of heparin-induced thrombocytopenia. Expert Rev Hematol 2015; 8 (06) 837-849
- 2 Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7 (Suppl. 01) 9-12
- 3 Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost 2017; 15 (11) 2099-2114
- 4 Cuker A, Arepally GM, Chong BH. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2018; 2 (22) 3360-3392
- 5 Schindewolf M, Steindl J, Beyer-Westendorf J. et al. Use of fondaparinux off- label or approved anticoagulants for management of heparin- induced thrombocytopenia. J Am Coll Cardiol 2017; 70 (21) 2636-2648
- 6 Poudel DR, Ghimire S, Dhital R, Forman DA, Warkentin TE. Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review. Platelets 2017; 28 (06) 614-620
- 7 Tvito A, Bakchoul T, Rowe JM, Greinacher A, Ganzel C. Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment. Am J Hematol 2015; 90 (07) 675-678
- 8 Linkins LA, Warkentin TE, Pai M. et al. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. J Thromb Haemost 2016; 14 (06) 1206-1210
- 9 Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood 2017; 130 (09) 1104-1113
- 10 Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4 (04) 759-765
- 11 Legnani C, Cini M, Pili C, Boggian O, Frascaro M, Palareti G. Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. Thromb Haemost 2010; 104 (02) 402-409
- 12 Schindewolf M, Steindl J, Beyer-Westendorf J. et al. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study. Thromb Res 2014; 134 (01) 29-35
- 13 Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood 2015; 125 (06) 924-929
- 14 Cohen AT, Bauersachs R. Rivaroxaban and the EINSTEIN clinical trial programme. Blood Coagul Fibrinolysis 2019; 30 (03) 85-95
- 15 Krauel K, Hackbarth C, Fürll B, Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 2012; 119 (05) 1248-1255
- 16 Sartori M, Favaretto E, Cini M, Legnani C, Cosmi B. Rivaroxaban in the treatment of heparin-induced thrombocytopenia. J Thromb Thrombolysis 2015; 40 (03) 392-394
- 17 Manji F, Warkentin TE, Sheppard JI, Lee A. Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban. Platelets 2020; 31 (01) 124-127
- 18 Bakchoul T, Borst O, Riessen R. et al. Autoimmune heparin-induced thrombocytopenia after transcatheter aortic valve implantation: successful treatment with adjunct high-dose intravenous immunoglobulin. TH Open 2019; 3 (02) e200-e202
- 19 Mian H, Warkentin TE, Sheppard JI. et al. Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma. Blood 2017; 130 (14) 1679-1682
- 20 ARIXTRA. Accessed 28 April 2020 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021345s010lbl.pdf